Class
Pan-ERR Agonist (ERRα / ERRβ / ERRγ)
Molecular Weight
~350 Da (small molecule)
Half-life
Under investigation
Purity
≥98% (HPLC)
Form
Powder (DMSO-soluble)
Storage
−20°C, DMSO-soluble
Reconstitution
DMSO then dilute in vehicle
Mechanism of action
SLU-PP-332 is a synthetic pan-agonist for all three estrogen-related receptors (ERRα, ERRβ, ERRγ) — nuclear receptors that act as master regulators of mitochondrial biogenesis and oxidative metabolism. Unlike classical estrogen receptors, ERRs are activated by metabolic signals, not estrogen. SLU-PP-332 activation drives transcription of genes involved in fatty acid oxidation, mitochondrial biogenesis via the PGC-1α pathway, and oxidative phosphorylation — pharmacologically inducing a "trained endurance" metabolic phenotype.
⚠️ For Research Use Only — described exclusively for in vitro and laboratory research by qualified researchers. Not for human or veterinary use. Informational only; does not constitute medical advice or imply efficacy in humans.
Research highlights
+70%
Running endurance increase in treated mice (Skaggs 2023)
PGC-1α
Mitochondrial biogenesis pathway activation
β-ox
Increased fatty acid oxidation in muscle and cardiac tissue
Fiber shift
Fast-to-slow twitch fiber type conversion evidence
Research notes
- Skaggs Institute 2023: Mice treated with SLU-PP-332 showed 70% increase in running distance and elevated resting metabolic rate.
- Mitochondrial biogenesis: Upregulation of PGC-1α, SIRT1, and downstream oxidative phosphorylation gene networks.
- Cardiac protection: Improved cardiac hypertrophy and heart failure models via ERR-mediated fatty acid utilization.
- Exercise mimetic: Behavioral and molecular overlap with endurance exercise training observed in multiple tissue types.
- Selectivity: Pan-ERR activation may offer broader metabolic modulation than selective ERRα agonists studied previously.
